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Prospective epidemiologic analysis of triazole-resistant 
nosocomial Candida glabrata isolated from patients at 
a comprehensive cancer center 
Amar Safdar,(l,*) Donald Armstrong,(r) Emily W. Gross,(3) David S. Perlin(3) 
Objective: The emergence of Candida glubrutu infections among patients with compromised immunity has become 
a serious concern, especially at centers caring for individuals with cancer. 
Methods: During a prospective evaluation of Cundidu species associated with either clinically significant colonization 
or infection, 26.9% of C. glubrutu isolates showed in vitro resistance to fluconazole (MIC of 264 Fg/ml). 
Results: Antifungal susceptibility profiles and genetic fingerprinting analysis performed by randomly amplified 
polymorphic DNA (RAPD) techniques confirmed low-probability of phenotypic and genotypic relatedness among 
nosocomial C. glubrutu isolates. 
Conclusions: Presence of polyclonal strains of C. glubrutu in patients at our hospital was probably related to selection 
of resistant yeasts from environmental pool rather than monoclonal expansion or clustering of multi-drug resistant 
C. glabratu in high-risk patients. 
Int J Infect Dis 2002; 6: 196-201 
INTRODUCTION 
Systemic candidiasis is a serious complication in patients 
undergoing therapy for cancer.l During the 1990s a 
species shift in the non-Cundidu ulbicans group was 
reported from centers caring for patients with malig- 
nancy as C. glabrutu, C. krusei and C. tropicalis became 
more frequent.2-4 The morbidity and mortality associated 
with these infections was comparable to those of 
systemic diseases due to C. ulbicans.24 In the last decade, 
reports of hematogenous candidiasis due to fluconazole- 
resistant C. glubrutu also became more frequent.5,6 This 
has caused uncertainty in determining appropriate pro- 
phylactic, preemptive and empirical antifungal therapy 
with triazole-based agents, especially in highly susceptible 
individuals such as those with hematologic malignancy 
or severe granulocytopenia, or recipients of allogeneic 
marrow or organ transplantation. 
The prevalence of C. glubruta has increased, and 
there are concerns about interpatient spread among 
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highly susceptible hospitalized individuals, especially 
of multiresistant strains. We performed a prospective 
evaluation of C. glubrutu to determine the probability of 
monoclonal expansion or clustering of fluconazole- 
resistant strains in patients at a cancer center. 
MATERIALS AND METHODS 
All clinical isolates from patients at Memorial Sloan- 
Kettering Cancer Center (MSKCC) from 1 July to 
31 December 1998 were evaluated for C. glubratu. 
Specimens from sterile body sites and those with pro- 
minent colonization (250 colonies of Cundidu) from 
nonsterile sources were included in this study. Patient 
data were retrieved from hospital charts, and com- 
puterized data systems. All specimens were initially 
processed at the MSKCC microbiology laboratory, 
which isolated and identified Cundida species. Species 
re-identification (under code) and testing of susceptibility 
to a panel of antifungal agents were conducted at the 
New York State Mycology Laboratories, Albany, New 
York, as described in previous reports.7 Genotyping was 
carried out at the Public Health Research Institute, New 
York, and dendrogram analysis was undertaken at the 
South Carolina Department of Health and Environment 
Control, Bureau of Laboratories, Columbia, South 
Carolina. 
C. glubrutu isolates were considered phenotypically 
distinct in the presence of a two or more dilution 
difference for ~2 antifungals. Yeast strains were con- 
sidered genetically non-related in the event of >4 band 
disparity and area-sensitive similarity coefficient (SAB) 
< 82.1 obtained by random amplified polymorphic DNA 
(RAPD) or arbitrarily primed PCR analyses.8 
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Figure 1. Molecular fingerprinting by RAPD analysis utilizing two random primers, 5’ AAC GCG CAA C and 5’ GAG GGT 
GGN GGN TCT. Genetic relatedness was confirmed by dendrogram analysis (Molecular Analyst Fingerprinting Plus Software, Bio-Rad 
laboratories, Hercules, CA, USA). Band positions between 100 to 3000 base pairs (DNA molecular weight marker XIV, Roche 
Diagnostics Corp., Indianapolis, IN, USA) were computed by area-sensitive similarity coefficient 6~s) with 1.0 optimization. C. 
glabrata isolates with !& values ~82.1, or ~4 band discrepancy, were considered to have a low probability of genetic relatedness. 
Table 1. Characteristics of nosocomial isolates of Candida glabrata with high-level in vitro triazole resistance 
Underlying Source of 
Patients Age-Sex cancer WBC specimens Nuconazole ltraconazole Ketoconazole Amphotericin 
1 46 M NHL-BMT 5.1 Bronchial wash 64 >I6 2 0.5 
2 91 F None 5.6 Oro-Pharynx 64 16 16 0.25 
3 74 F Colon 14.4 Bile 64 4 2 0.25 
4 52 F Gall bladder 5 Bile 64 2 2 0.25 
5 72 M Head and Neck 6.3 Sputum 64 2 2 0.25 
6 77 M NHL 1.2 Penial lesion 64 0.25 0.25 0.25 
7 70 F Lung 12.3 Bronchial wash 64 1 1 0.25 
8 32 M Ovarian 3 Bronchial wash 64 16 4 0.25 
9 51 F CML-BMT 13.8 Bronchial lavage 264 4 4 0.25 
10 71 M NHL 17.8 Urine >64 0.5 0.12 0.25 
11 82 F Breast 11 Urine 64 2 2 0.12 
12 60 F MDS 0.2 Bronchial wash 64 2 2 0.5 
13 47 M AML 0.7 Bronchial wash >64 4 2 0.25 
14 46 F MDS 0.1 Blood 264 16 4 0.25 
NHL=Non Hodgkin’s lymphoma; BMT=allogeneic marrow transplantation; CML=chronic myelogenous leukemia; MDS=myelodysplastic syndrome. 
Antifungal drug susceptibility was performed by microdilution test and MIC are determined in micograms/ml. 
RESULTS 
From 1 July to 31 December 1998, 52 clinical isolates 
of C. glubrutu were evaluated prospectively at our 
institution. Fourteen (26.9%) patients had fluconazole- 
resistant C. glubrutu associated with either prominent 
colonization or invasive disease. We did not find an 
association between prior fluconazole exposure and 
subsequent development of triazole resistance among 
C. glabrata strains: however, such an association was 
noticed among C. albicans strains.7 
In Table 1, characteristics of 14 hospitalized patients 
and the antifungal susceptibility profile of C. ghbratu are 
presented. The median age among six male and eight 
female patients was 62.2k16.9 years. Three were pro- 
foundly neutropenic (absolute neutrophil count < 100 
cells/mm3). Hematologic malignancy was present in seven 
(50%) and two underwent allogeneic marrow trans- 
plantation for non-Hodgkin’s lymphoma and chronic 
myelogenous leukemia. Respiratory tract specimens 
accounted for half of all clinical samples from which 
fluconazole-resistant C. glabrata was isolated (six 
bronchial washes, and bronchioalveolar lavage and 
sputum one each). 
Twelve C. glubrutu strains were resistant to itra- 
conazole (MIC > 1 p,g/mL). Discordance in the triazole- 
based antifungal susceptibility profiles was seen in 
patient 6 and patient 10. Ninety-three per cent of all 
isolates were susceptible to ketoconazole, and resistance 
to amphotericin B (MIC >l mg/mL) was not seen. 
Ten (71.4%) C. glabrutu isolates were phenotypically 
distinct, while four C’. glabrata strains from patients 4,5, 
11 and 12 had identical antifungal susceptibility profiles 
(Table 1). 
200 International Journal of Infectious Diseases I Volume 6, Number 3.2002 
Molecular fingerprinting of 10 phenotypically 
distinct C. glabratu isolates is presented in Figure 1. 
The genetic relatedness was computed by area-sensitive 
coefficient (SAB). An S AB of 100 represents identical 
yeast strains, and an SAB of 0.0 represents no DNA band 
position match between strains of C. glubratu. In these 
10 isolates, SAB ranged from 82.1 (4 band differences) to 
46.6 (19 band differences) (Figure 1). The average SAB 
for 10 non-genetically related, multiresistant C. glubrutu 
strains was 63.7 2 8.2. 
DISCUSSION 
Hematogenous candidiasis most frequently arises from 
the host’s endogenous flora, and colonization with 
Cundidu species is considered an important predictor 
of future systemic infection.lO~ll Large yeast reservoirs 
comprising multiple body sites and high volumes of 
colonization may increase the probability of systemic 
invasion, especially in susceptible individuals.1°,12 Patients 
undergoing treatment for hematologic malignancy or 
those with refractory solid-organ cancer, and recipients 
of allogeneic marrow and organ transplantation, are 
especially vulnerable. lo We report the results of an 
epidemiologic study to evaluate possible clustering 
of triazole-resistant C. glubrutu strains isolated from 
hospitalized cancer patients. 
Identification and monitoring of nosocomial spread 
among resistant Candida species is critical in deter- 
mining appropriate measures for interruption of further 
transmission. Genetic relatedness by RAPD analysis is 
an effective tool in this setting.13 Molecular epidemio- 
logic studies of C. albicans associated with bloodstream 
invasion have shown that hematogenous candidiasis due 
to a single dominant strain is extremely rare.14 Candidu 
infections in patients at a single center usually coincide 
with yeast isolates from the host’s endogenous flora.14 
Similarly, we did not observe a temporal clustering of 
a single dominant fluconazole-resistant C. glubrata 
strain associated with either prominent colonization or 
invasive disease in these patients with cancer. 
The strong genetic differences in populations of C. 
albicuns obtained from either colonization or systemic 
infection in patients at various units within the same 
hospital, or a cohort of patients with similar risk factors 
such as AIDS and cancer, have been described.15 Poly- 
clonal strain variability among fluconazole-susceptible 
C. glabrutu strains isolated from patients with urinary 
tract colonization was also reported recently.16,‘7 The 
fate of multiresistant Cundida species, especially C. 
glabrata in hospitalized individuals, and underlying 
mechanisms of nosocomial distribution within an 
institution, are uncertain. Interpatient spread and 
nosocomial outbreaks of invasive candidiasis have been 
reported and frequently traced back to the hands of 
health care workers.1s,19 
The significant strain variation within fluconazole- 
resistant C. glabratu in patients at MSKCC was in- 
teresting, although not unexpected. Others have shown 
similar multiplicity of DNA subtypes, e.g. multi-strain, 
triazole-resistant C. albicans isolated from AIDS patients 
with recurrent oropharyngeal candidiasis.20 Our data 
suggest that polyclonal strains of multiresistant C. 
glubrutu obtained from hospitalized cancer patients 
represent a lack of clustering of dominant strains in 
a susceptible population of patients. Alternatively, the 
appearance of different DNA subtypes may represent 
microevolution within a stable dominant C. glabratu 
subgenotype associated with colonization or infection 
in our patients with cancer. 2o Similarly, ‘substrain shuff- 
ling”‘, as proposed for women with recurrent Cundidu 
vaginitis21 could be responsible for the genotypic 
disparity observed in our group. 
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